Reduced expressions of apoptosis-related proteins TRAIL, Bcl-2, and TNFR1 in NK cells of juvenile-onset systemic lupus erythematosus patients: relations with disease activity, nephritis, and neuropsychiatric involvement

Background Lupus pathogenesis is mainly ascribed to increased production and/or impaired clearance of dead cell debris. Although self-reactive T and B lymphocytes are critically linked to lupus development, neutrophils, monocytes, and natural killer (NK) cells have also been implicated. This study assessed apoptosis-related protein expressions in NK cells of patients with juvenile-onset systemic lupus erythematosus (jSLE) and relations to disease activity parameters, nephritis, and neuropsychiatric involvement. Methods Thirty-six patients with jSLE, 13 juvenile dermatomyositis (JDM) inflammatory controls, and nine healthy controls had Fas, FasL, TRAIL, TNFR1, Bcl-2, Bax, Bim, and caspase-3 expressions in NK cells (CD3−CD16+CD56+) simultaneously determined by flow cytometry. Disease activity parameters included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, erythrocyte sedimentation rate, C-reactive protein level, anti-double strain DNA antibody level, complement fractions C3 and C4 levels. Results Patients with jSLE had a profile of significantly reduced expression of TRAIL, Bcl-2, and TNFR1 proteins in NK cells when compared to healthy controls. Similar profile was observed in patients with jSLE with active disease, positive anti-dsDNA, nephritis, and without neuropsychiatric involvement. Patients with jSLE with positive anti-dsDNA also had reduced expression of Bax in NK cells when compared healthy controls and to those with negative anti-dsDNA. Yet, patients with jSLE with negative anti-dsDNA had reduced mean fluorescence intensity (MFI) of Bim in NK cells compared to healthy controls. Patients with jSLE with nephritis also had reduced MFI of Fas in NK cells when compared to those without nephritis. In addition, in patients with jSLE, the proportion of FasL-expressing NK cells directly correlated with the SLEDAI-2K score (rs = 0.6, p = 0.002) and inversely correlated with the C3 levels (rs = −0.5, p = 0.007). Moreover, patients with jSLE had increased NK cell percentage and caspase-3 protein expression in NK cells when compared to JDM controls. Conclusion This study extends to NK cells an altered profile of TRAIL, Bcl-2, TNFR1, Fas, FasL, Bax, Bim, and caspase-3 proteins in patients with jSLE, particularly in those with active disease, positive anti-dsDNA, nephritis, and without neuropsychiatric involvement. This change in apoptosis-related protein expressions may contribute to the defective functions of NK cells and, consequently, to lupus development. The full clarification of the role of NK cells in jSLE pathogenesis may pave the way for new therapies like those of NK cell–based.

[1]  C. Hedrich,et al.  Current views on lupus in children , 2022, Current opinion in rheumatology.

[2]  J. Pardo,et al.  All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity , 2022, Frontiers in Immunology.

[3]  I. Wicks,et al.  Natural killer cells in inflammatory autoimmune diseases , 2021, Clinical & translational immunology.

[4]  W. Cui,et al.  Natural killer cells and their function in Takayasu's arteritis. , 2020, Clinical and experimental rheumatology.

[5]  J. Demengeot,et al.  LRBA deficiency: a new genetic cause of monogenic lupus , 2019, Annals of the rheumatic diseases.

[6]  M. Beresford,et al.  Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. , 2019, Clinical immunology.

[7]  C. Silva,et al.  Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus , 2019, Clinical Rheumatology.

[8]  H. Hetta,et al.  Natural Killer and Natural Killer T Cells in Juvenile Systemic Lupus Erythematosus: Relation to Disease Activity and Progression , 2019, Archivum Immunologiae et Therapiae Experimentalis.

[9]  M. Kiss,et al.  Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus , 2017, Clinical Rheumatology.

[10]  E. Bonfá,et al.  Features of 847 Childhood‐Onset Systemic Lupus Erythematosus Patients in Three Age Groups at Diagnosis: A Brazilian Multicenter Study , 2016, Arthritis care & research.

[11]  S. Bando,et al.  Molecular characterization of the complement C1q, C2 and C4 genes in Brazilian patients with juvenile systemic lupus erythematosus , 2015, Clinics.

[12]  C. Suh,et al.  Incomplete clearance of apoptotic cells in systemic lupus erythematosus: pathogenic role and potential biomarker , 2015, International journal of rheumatic diseases.

[13]  N. Kholoussi,et al.  TRAIL mRNA expression in peripheral blood mononuclear cells of Egyptian SLE patients. , 2013, Gene.

[14]  S. Carrasco,et al.  Reduced expressions of Fas and Bcl-2 proteins in CD14+ monocytes and normal CD14 soluble levels in juvenile systemic lupus erythematosus , 2013, Lupus.

[15]  A. Paiva,et al.  NK cells dysfunction in systemic lupus erythematosus: relation to disease activity , 2013, Clinical Rheumatology.

[16]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[17]  Ying Guo,et al.  Increased apoptosis and expression of FasL, Bax and caspase-3 in human lupus nephritis class II and IV. , 2012, Journal of nephrology.

[18]  A. Coutinho,et al.  Complement and antibody primary immunodeficiency in juvenile systemic lupus erythematosus patients , 2011, Lupus.

[19]  M. Kiss,et al.  The Role of Apoptosis Proteins and Complement Components in the Etiopathogenesis of Systemic Lupus Erythematosus , 2010, Clinics.

[20]  R. Moots,et al.  The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[21]  Hyung-Sik Kang,et al.  Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[22]  J. Vlag,et al.  Apoptosis in the pathogenesis of systemic lupus erythematosus , 2008, Lupus.

[23]  J. B. Oliveira,et al.  Understanding Systemic Lupus Erythematosus Physiopathology in the Light of Primary Immunodeficiencies , 2008, Journal of Clinical Immunology.

[24]  M. Kiss,et al.  Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus. , 2007, The Journal of rheumatology.

[25]  M. Kiss,et al.  Increased Fas and Bcl-2 Expression on Peripheral Blood T and B Lymphocytes from Juvenile-Onset Systemic Lupus Erythematosus, but not from Juvenile Rheumatoid Arthritis and Juvenile Dermatomyositis , 2006, Clinical & developmental immunology.

[26]  C. Cudrici,et al.  Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. , 2005, Clinical immunology.

[27]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[28]  S. Rantapaa-Dahlqvist,et al.  The Regulation of FasL Expression—A Distinguishing Feature Between Monocytes and T Lymphocytes/NK Cells with Possible Implications for SLE , 2001, Journal of Clinical Immunology.

[29]  T. Yamamura,et al.  Natural killer type 2 bias in remission of multiple sclerosis. , 2001, The Journal of clinical investigation.

[30]  P. Lydyard,et al.  Lack of NK cells in lupus patients with renal involvement , 1997, Lupus.

[31]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[32]  C. Ware,et al.  Fas involvement in human NK cell apoptosis: lack of a requirement for CD16‐mediated events , 1997, Journal of leukocyte biology.

[33]  K. Takeda,et al.  The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms , 1993, The Journal of experimental medicine.

[34]  A. Strasser,et al.  Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. , 2006, Current directions in autoimmunity.

[35]  T. Brannagan,et al.  Polymyositis and dermatomyositis , 2002 .

[36]  J. Scholze,et al.  Arthritis & Rheumatism , 2002 .

[37]  K. Koike,et al.  A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. , 1996, The Journal of rheumatology.